Phase III randomized trial of stereotactic ablative radiotherapy (SAbR) for oligometastatic advanced renal carcinoma (EA8211-SOAR).

被引：1
|
作者：
Kim, Se Eun
Cole, Suzanne
Wulff-Burchfield, Elizabeth Marie
Wentland, Andrew
Hannan, Mu-Han
Kapur, Payal
Shevrin, Daniel
Gurley, Tami
Lin, John Kent
Brugarolas, James
Timmerman, Robert D.
Mckay, Rana R.
Wagner, Lynne I.
Haas, Naomi B.
Carducci, Michael Anthony
机构：
[1] Univ Texas Southwestern Med Ctr, Dallas, TX USA
[2] DFCI PCC Fellowship Program Attendings, Boston, MA USA
[3] Univ Kansas, Med Ctr, Westwood, KS USA
[4] Univ Wisconsin, Madison, WI USA
[5] Univ Texas Southwestern, Dept Pathol, Dallas, TX USA
[6] Northshore Univ Hlth Syst, Evanston, IL USA
[7] UT Southwestern Med Ctr, Dallas, TX USA
[8] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
[9] Univ Texas Southwestern, Div Hematol & Oncol, Dept Internal Med, Dallas, TX USA
[10] Univ Texas Southwestern Med Ctr, Radiat Oncol, Dallas, TX USA
[11] Univ Calif San Diego, La Jolla, CA USA
[12] Wake Forest Univ, Sch Med, Winston Salem, NC USA
[13] Univ Penn, Abramson Canc Ctr, Philadelphia, PA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 4_SUPPL期
关键词：
261-566-11347; 261-137-3222-3876-5567; 283-424-3231; 261-492-3532-2370-7650-2700; 3282-270-434-2806; 261-492-199; 261-137; 11; 10; 6; 5; 4;
D O I：
10.1200/JCO.2024.42.4_suppl.TPS489
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：TPS489 / TPS489
页数：1
相关论文
共 50 条
  • [31] SARON: Stereotactic Ablative Radiotherapy for Oligometastatic Non-small cell lung cancer (NSCLC): a randomised phase III trial
    McDonald, F.
    Mak, K. M.
    Teague, J.
    Landau, D.
    Hanna, G.
    Farrelly, L.
    Counsell, N.
    LUNG CANCER, 2020, 139 : S91 - S91
  • [32] Cost-minimization analysis of the GORTEC 2014-04 randomized phase II study of stereotactic ablative radiotherapy (SABR) or chemotherapy-SABR in oligometastatic head and neck cancer
    Nerich, Virginie
    Falcoz, Antoine
    Nadin, Lawrence
    Meurisse, Aurelia
    Pechery, Adeline
    Bourhis, Jean
    Sun, Xu-Shan
    Thariat, Juliette
    RADIOTHERAPY AND ONCOLOGY, 2025, 204
  • [33] Population-based phase II trial of stereotactic ablative radiotherapy (SABR) for up to 5 oligometastases: SABR-5
    Robert Olson
    Mitchell Liu
    Alanah Bergman
    Sonya Lam
    Fred Hsu
    Benjamin Mou
    Tanya Berrang
    Ante Mestrovic
    Nick Chng
    Derek Hyde
    Quinn Matthews
    Chad Lund
    Daniel Glick
    Howard Pai
    Parminder Basran
    Hannah Carolan
    Boris Valev
    Shilo Lefresene
    Scott Tyldesley
    Devin Schellenberg
    BMC Cancer, 18
  • [34] Population-based phase II trial of stereotactic ablative radiotherapy (SABR) for up to 5 oligometastases: SABR-5
    Olson, Robert
    Liu, Mitchell
    Bergman, Alanah
    Lam, Sonya
    Hsu, Fred
    Mou, Benjamin
    Berrang, Tanya
    Mestrovic, Ante
    Chng, Nick
    Hyde, Derek
    Matthews, Quinn
    Lund, Chad
    Glick, Daniel
    Pai, Howard
    Basran, Parminder
    Carolan, Hannah
    Valev, Boris
    Lefresene, Shilo
    Tyldesley, Scott
    Schellenberg, Devin
    BMC CANCER, 2018, 18
  • [35] POPULATION BASED PHASE II TRIAL OF STEREOTACTIC ABLATIVE RADIOTHERAPY (SABR) FOR UP TO FIVE OLIGOMETASTASES: PRELIMINARY RESULTS OF THE SABR-5 TRIAL
    Olson, Robert
    Jiang, Will
    Liu, Mitchell
    Bergman, Alanah
    Schellenberg, Devin
    Mou, Benjamin
    Alexander, Abraham
    Carolan, Hannah
    Hsu, Fred
    Miller, Stacy
    Atrchian, Siavash
    Chan, Elisa
    Ho, Clement
    Mohamed, Islam
    Lin, Angela
    Berrang, Tanya
    Bang, Andrew
    Chng, Nick
    Matthews, Quinn
    Mestrovic, Ante
    Hyde, Derek
    Huang, Vicky
    Lund, Chad
    Pai, Howard
    Valev, Boris
    Lefresne, Shilo
    Tyldesley, Scott
    RADIOTHERAPY AND ONCOLOGY, 2021, 163 : S4 - S4
  • [36] A prospective phase I dose-escalation trial of stereotactic ablative radiotherapy (SABR) as an alternative to cytoreductive nephrectomy for inoperable patients with metastatic renal cell carcinoma
    Correa, Rohann J. M.
    Ahmad, Belal
    Warner, Andrew
    Johnson, Craig
    MacKenzie, Mary J.
    Pautler, Stephen E.
    Bauman, Glenn S.
    Rodrigues, George B.
    Louie, Alexander V.
    RADIATION ONCOLOGY, 2018, 13
  • [37] A prospective phase I dose-escalation trial of stereotactic ablative radiotherapy (SABR) as an alternative to cytoreductive nephrectomy for inoperable patients with metastatic renal cell carcinoma
    Rohann J. M. Correa
    Belal Ahmad
    Andrew Warner
    Craig Johnson
    Mary J. MacKenzie
    Stephen E. Pautler
    Glenn S. Bauman
    George B. Rodrigues
    Alexander V. Louie
    Radiation Oncology, 13
  • [38] Population Based Phase II Trial of Stereotactic Ablative Radiotherapy (SABR) for up to 5 Oligometastases: Preliminary Results of the SABR-5 Trial
    Olson, R. A.
    Jiang, W.
    Liu, M. C.
    Bergman, A.
    Schellenberg, D.
    Mou, B.
    Alexander, A. S.
    Carolan, H.
    Hsu, F.
    Miller, S.
    Atrchian, S.
    Chan, E. K.
    Ho, C.
    Mohamed, I. G.
    Lin, A.
    Berrang, T.
    Bang, A.
    Chng, N.
    Matthews, Q.
    Huang, V.
    Mestrovic, T.
    Hyde, D.
    Lund, C. R.
    Pai, H. H.
    Valev, B.
    Lefresne, S.
    Tyldesley, S.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2021, 111 (03): : S4 - S4
  • [39] Cost effectiveness of stereotactic ablative radiotherapy (SABR) alone in comparison with systemic treatment and SABR in oligometastatic head and neck cancer in the GORTEC 2014-04 OMET randomized phase II study
    Thariat, J.
    Falcoz, A.
    Nadin, L.
    Bourhis, J.
    Sun, X.
    Nerich, V.
    ANNALS OF ONCOLOGY, 2024, 35 : S634 - S634
  • [40] SARON: Stereotactic Ablative Radiotherapy for Oligometastatic Non-small cell lung cancer (NSCLC). A UK randomised phase III trial
    Landau, D. B.
    Hughes, L.
    Ngai, Y.
    Hanna, G. G.
    Conibear, J.
    Farrelly, L.
    Counsell, N.
    LUNG CANCER, 2017, 103 : S54 - S54
12345